Clinical Trial

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main objective of this trial is to evaluate the safety and immunogenicity of mRNA-1189 after intradermal and intramuscular delivery.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-13.
Status change: Not Yet Recruiting → Recruiting 2026-03-20
Trial Details
NCT Number NCT07478952
Lead Sponsor ModernaTX, Inc.
Conditions Epstein-Barr Virus
Enrollment 120 participants
Start Date 2026-03-17
Primary Completion 2027-05-15 (estimated)
Study Completion 2027-05-15 (estimated)
Updated on ClinicalTrials.gov 2026-03-24